<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="migraine/PMC5515721/results/search/drugs/results.xml">
  <result pre="5515721 pmid: 28721545 776 doi: 10.1186/s10194-017-0776-4 : Research Article Is" exact="topiramate" post="effective for migraine prevention in patients less than 18"/>
  <result pre="assess the currently published data pertaining to the efficacy of" exact="topiramate" post="for migraine prevention in patients less than 18 years"/>
  <result pre="465 patients. Of these patients, 329 were included in the" exact="topiramate" post="group, and 136 were included in the placebo group."/>
  <result pre="the placebo group. This meta-analysis revealed that compared with placebo," exact="topiramate" post="failed to decrease the number of patients experiencing a"/>
  <result pre="Higher rates of side effects and adverse events in the" exact="topiramate" post="group than in the placebo group were observed in"/>
  <result pre="migraines in patients less than 18 years of age, and" exact="topiramate" post="may lead to more side effects or adverse events"/>
  <result pre="United States since 2004 [ 7]. The exact mechanism of" exact="topiramate" post="in the treatment of migraine is unknown, although it"/>
  <result pre="unknown, although it may be associated with the influence of" exact="topiramate" post="on pain transmission in the trigeminocervical complex and the"/>
  <result pre="series and open-label trials [ 9– 13] have shown that" exact="topiramate" post="served as a preventive treatment for pediatric migraines, while"/>
  <result pre="[ 14] indicated that there were no significant differences between" exact="topiramate" post="and placebo in the prevention of pediatric migraine. Hence,"/>
  <result pre="of randomized controlled trials (RCTs) to evaluate the efficacy of" exact="topiramate" post="for the prevention of migraine in patients less than"/>
  <result pre="Library (inception to April 2017) to retrieve the RCTs of" exact="topiramate" post="in migraine prevention for patients less than 18 years"/>
  <result pre="the following criteria: (1) the study was a trial comparing" exact="topiramate" post="with placebo in migraine patients, (2) the study had"/>
  <result pre="a clinical RCT, (5) the intent-to-treat population numbers in the" exact="topiramate" post="and placebo groups were provided, and (6) the number"/>
  <result pre="did not contain placebo (for example, the trial only used" exact="propranolol" post="or sodium valproate as a control), and (5) the"/>
  <result pre="placebo (for example, the trial only used propranolol or sodium" exact="valproate" post="as a control), and (5) the trial involved adults"/>
  <result pre="The main information, including the numbers of participants in the" exact="topiramate" post="and placebo groups, the diagnostic tool, the dose and"/>
  <result pre="total of 465 randomized patients, including 329 patients in the" exact="topiramate" post="group and 136 in the placebo group, and the"/>
  <result pre="[ 21]. One trial [ 18] used 2 doses of" exact="topiramate" post="versus placebo. Another trial [ 14] used amitriptyline and"/>
  <result pre="doses of topiramate versus placebo. Another trial [ 14] used" exact="amitriptyline" post="and topiramate as the two treatment arms, and we"/>
  <result pre="topiramate versus placebo. Another trial [ 14] used amitriptyline and" exact="topiramate" post="as the two treatment arms, and we extracted the"/>
  <result pre="the two treatment arms, and we extracted the results of" exact="topiramate" post="versus placebo. The duration of the included trials consisted"/>
  <result pre="included patients who ended trial early †35 subjects treated with" exact="topiramate" post="at 50 mg/day, 35 subjects treated with topiramate at"/>
  <result pre="treated with topiramate at 50 mg/day, 35 subjects treated with" exact="topiramate" post="at 100 mg/day Risk of bias of the included"/>
  <result pre="Table 2, all 4 included trials investigated the effects of" exact="topiramate" post="on migraine prevention via the numbers of patients experiencing"/>
  <result pre="meta-analysis show that, there were no significant differences between the" exact="topiramate" post="and placebo groups in terms of the numbers of"/>
  <result pre="Forest plot of comparison:≥50% Relative reduction in headache frequency of" exact="topiramate" post="versus placebo Secondary outcomes All 4 trials included in"/>
  <result pre="found no significant difference in mean headache days between the" exact="topiramate" post="and placebo groups ( n = 465, MD = −0.77, 95% CI = [−2.31, 0.76],"/>
  <result pre="Forest plot of comparison: headache days per 28-day period of" exact="topiramate" post="versus placebo Fig. 5 Forest plot of comparison: PedMIDAS"/>
  <result pre="placebo Fig. 5 Forest plot of comparison: PedMIDAS score of" exact="topiramate" post="versus placebo Side effects and adverse events All included"/>
  <result pre="overall incidence of most adverse events was higher in the" exact="topiramate" post="group than in the placebo group, with ten of"/>
  <result pre="suicide attempts and other disabling events) occurring only in the" exact="topiramate" post="group. Detailed side effects and adverse events and their"/>
  <result pre="6b, n = 380, RR = 4.38, 95% CI = [1.92, 10.01], Z = 3.51, P = 0.0005) in the" exact="topiramate" post="group. The evidence collected in our meta-analysis shows no"/>
  <result pre="event aValues expressed as N (%) #Reported only in the" exact="topiramate" post="treatment group Fig. 6 Forest plot of comparison: Side"/>
  <result pre="tract infection, dizziness, fever, nausea, pharyngitis, sinusitis and somnolence) of" exact="topiramate" post="versus placebo(*There was a significant difference between topiramate and"/>
  <result pre="somnolence) of topiramate versus placebo(*There was a significant difference between" exact="topiramate" post="and placebo groups) Publication bias Since our meta-analysis included"/>
  <result pre="not be performed. Discussion This meta-analysis examined the efficacy of" exact="topiramate" post="in comparison with placebo for the prevention of migraines"/>
  <result pre="March 2014, the U.S. Food and Drug Administration (FDA) approved" exact="topiramate" post="for migraine prevention in the population aged 12 to"/>
  <result pre="of reduced mean headache days in a 28-day period showed" exact="topiramate" post="as more efficacious than placebo in our meta-analysis of"/>
  <result pre="meta-analysis of four RCTs. According to the definition [ 22]," exact="topiramate" post="showed no statistically significant benefit over placebo in reducing"/>
  <result pre="treatment period. In fact, the 50% response rate of the" exact="topiramate" post="group in 2 trials [ 14, 20] was not"/>
  <result pre="18] a similar result was presented for the 50 mg/day" exact="topiramate" post="treatment group. The finding conflicts with the outcomes of"/>
  <result pre="is higher than the rates reported in previous studies of" exact="topiramate" post="preventing adult migraine (0–34.2%) [ 28– 31]. Rothner et"/>
  <result pre="adults deserves further discussion. (2) The minimum age at which" exact="topiramate" post="was approved for treatment of migraine was 12 years"/>
  <result pre="meta- analysis. The second finding of our meta-analysis is that" exact="topiramate" post="decreased PedMIDAS scores in migraine patients. PedMIDAS is often"/>
  <result pre="alleviated by topiramate. However, mean PedMIDAS scores in both the" exact="topiramate" post="group and the placebo group decreased between baseline and"/>
  <result pre="the cause of the heterogeneity. As with all antiepileptic drugs," exact="topiramate" post="has many potential side effects or adverse events, some"/>
  <result pre="37]. The rate of adverse events in patients treated with" exact="topiramate" post="was higher than that with placebo in our included"/>
  <result pre="disorder or aphasia, occurred in adults and pediatric patients taking" exact="topiramate" post="in previous trials. Other adverse events, such as changes"/>
  <result pre="secondary closed angle glaucoma, have also been reported. In addition," exact="topiramate" post="(100 mg/day) was related to modest increases in psychomotor"/>
  <result pre="that has been observed in people taking antiepileptic drugs, including" exact="topiramate" post="[ 39]. Thus, while the pathomechanism of migraine is"/>
  <result pre="also be limitations. Conclusions This is the first meta-analysis of" exact="topiramate" post="for migraine prevention in patients less than 18 years"/>
  <result pre="patients less than 18 years of age. We found that" exact="topiramate" post="did not achieve a more effective clinical trial endpoint"/>
  <result pre="migraine in patients less than 18 years of age, and" exact="topiramate" post="was associated with more adverse events in the included"/>
  <result pre="329 330 10.1007/s13312-012-0040-6 22565082 11. Abbaskhanian ASHREAMS Effective dose of" exact="topiramate" post="in pediatric migraine prophylaxis In J Pediatr Neurosci 2012"/>
  <result pre="Divanizadeh MS Karimi M Mirouliaei M Shamszadeh A Topiramate and" exact="propranolol" post="for prophylaxis of migraine Indian J Pediatr 2013 80"/>
  <result pre="Powers SW Vockell ALB LeCates S Kabbouche M Effectiveness of" exact="topiramate" post="in the prevention of childhood headaches Headache 2002 42"/>
  <result pre="double-blind, placebo-controlled study to evaluate the efficacy and safety of" exact="topiramate" post="for migraine prevention in pediatric subjects 12 to 17"/>
  <result pre="Jordan D Karvois D Kamin M Efficacy and tolerability of" exact="topiramate" post="200 mg/d in the prevention of migraine with/without aura"/>
  <result pre="data from two pivotal controlled trials on the efficacy of" exact="topiramate" post="in the prevention of migraine J Am Osteopath Assoc"/>
  <result pre="P Singh S Goyal V Shukla G Behari M Low-dose" exact="topiramate" post="versus lamotrigine in migraine prophylaxis (the Lotolamp study) Headache"/>
  <result pre="S Goyal V Shukla G Behari M Low-dose topiramate versus" exact="lamotrigine" post="in migraine prophylaxis (the Lotolamp study) Headache 2007 47"/>
  <result pre="E Eerdekens M Bilder RM Ford L Cognitive effects of" exact="topiramate" post="in migraine patients aged 12 through 17 years Pediatr"/>
 </snippets>
</snippetsTree>
